Piper Sandler says Acceleron remains top pick » 18:1702/2702/27/20
Piper Sandler analyst…
Piper Sandler analyst Danielle Brill maintained an Overweight rating and $135 price target on Acceleron Pharma, as the reblozyl launch is now underway, and label expansion for MDS is expected by its April 4 PDUFA date. Brill said that while management is reportedly pleased with teh growth they are seeing, they are not anticipating meaningful revenue generation until later this year when MDS starts to ramp. The analyst added that a planned meeting with the FDA to discuss the next steps for development will be a "significant" catalyst, and that Acceleron remains a top pick ahead of sotatercept data at ATS.
Pfizer names Coca-Cola CEO to board of directors » 16:1902/2702/27/20
Pfizer (PFE) Compensation…
Pfizer (PFE) Compensation Committee and the Science and Technology Committee of Pfizer's Board. Mr. Quincey is Chairman and Chief Executive Officer of The Coca-Cola Company (KO). He has held the position of Chairman of the Board of The Coca-Cola Company since 2019 and CEO since 2017. Prior to becoming CEO, he served as President and Chief Operating Officer from August 2015 to 2017. Since Mr. Quincey joined The Coca-Cola Company in 1996, he has held a number of leadership roles around the world, including President of the Europe Group, President of the Mexico division and President of the South Latin division. Prior to joining Coca-Cola, he was a partner in strategy consulting at The Kalchas Group, a spinoff of Bain & Company and McKinsey. Mr. Quincey serves as vice co-chair of The Consumer Goods Forum and is a founding member of the New York Stock Exchange Board Advisory Council.
Acceleron Pharma reports Q4 EPS (44c), consensus (30c) » 16:0602/2702/27/20
Reports Q4 revenue…
Reports Q4 revenue $39.34M, consensus $35.89M. "2019 was a pivotal year for Acceleron as we achieved the most important milestone to date in our 16-year history-our first U.S. FDA approval," said Habib Dable, President and Chief Executive Officer of Acceleron. "In November, REBLOZYL(R) (luspatercept-aamt) became the first and only FDA approved erythroid maturation agent and is now indicated to treat anemia in adults with beta-thalassemia who require regular red blood cell transfusions. The approval of REBLOZYL(R) marks a huge victory for patients with beta-thalassemia, who-up until now-have been waiting for a better way to treat their anemia. It is also a validation of Acceleron's scientific platform leveraging our expertise in the TGF-beta superfamily of proteins and our unwavering commitment to develop and commercialize medicines to treat serious and rare diseases."
Pfizer upgraded to Buy from Hold at Standpoint Research » 14:3602/2702/27/20
Standpoint Research analyst Ronnie Moas upgraded Pfizer to Buy from Hold.
U.S. weighs special powers to ramp up output of protective masks, Reuters says » 14:3202/2702/27/20
HON, MMM, KMB, SPX, SPY, APT
U.S. President Donald…
U.S. President Donald Trump's administration is weighing invoking special powers through a law called the Defense Production Act to quickly expand domestic output of protective masks and clothing to fight the spread of coronavirus in the U.S., Reuters' Ted Hesson and Alexandra Alper reports, citing U.S. officials. The use of the law would mark an escalation of the White House's response to the outbreak, the authors note. Publicly traded companies that manufacture protective masks include Honeywell (HON), 3M (MMM), Kimberly-Clark (KMB) and Alpha Pro Tech (APT). Reference Link
Pfizer call volume above normal and directionally bullish » 11:2502/2702/27/20
Bullish option flow…
Bullish option flow detected in Pfizer with 18,360 calls trading, 1.3x expected, and implied vol increasing over 6 points to 31.33%. Jun-20 33 calls and 2/28 weekly 36 calls are the most active options, with total volume in those strikes near 3,700 contracts. The Put/Call Ratio is 0.31. Earnings are expected on April 28th.
Barclays biopharmaceuticals analysts to hold an analyst/industry conference call » 10:2102/2702/27/20
ABBV, XLRN, ALEC, ALLK, AMGN, APLT, BIIB, BMY, LLY, GILD, GOSS, MRK, MTEM, NBIX, PFE, REGN
Biopharmaceuticals Analysts Gould and Ang discuss launching coverage of the Biopharmaceuticals industry on an Analyst/Industry conference call to be held on February 27 at 11 am.
Mylan, Pfizer announce Sanjeev Narula as CFO of Viatris » 08:2002/2702/27/20
Mylan (MYL) and Pfizer…
Mylan (MYL) and Pfizer (PFE) announced that Sanjeev Narula, current CFO of Upjohn, a division of Pfizer, has been named incoming CFO of Viatris, the new company that will result from the planned combination of Mylan and Upjohn. Narula's 16-year history with Pfizer encompasses several financial leadership positions, where he has worked under the leadership of Pfizer's CFO and executive VP of business operations and global supply, Frank D'Amelio. At Upjohn, he has worked closely with incoming Viatris CEO Michael Goettler and has developed anunderstanding of financial and commercial dynamics across key geographies.
Pfizer, Mylan name Sanjeev Narula incoming CFO of Viatris » 08:1702/2702/27/20
Mylan (MYL) and Pfizer…
Mylan (MYL) and Pfizer (PFE) announced that Sanjeev Narula, current CFO of Upjohn, a division of Pfizer, has been named incoming CFO of Viatris, the new company that will result from the planned combination of Mylan and Upjohn. Upon closing, which is expected in mid-2020, Viatris will be a new champion for global health with a portfolio of approximately 3,000 brands and molecules and a commercial presence in 165 countries. Narula's strong, 16-year history with Pfizer encompasses several financial leadership positions, where he has worked under the leadership of Pfizer's CFO and Executive Vice President of Business Operations and Global Supply, Frank D'Amelio. At Upjohn, he has worked closely with incoming Viatris CEO Michael Goettler and has developed a deep understanding of financial and commercial dynamics across key geographies, including emerging markets, particularly China.
Mylan, Pfizer announce remaining appointees to Viatris board » 08:0902/2702/27/20
Mylan (MYL) and Pfizer…
Mylan (MYL) and Pfizer (PFE) announced the remaining appointees to the inaugural 13-member board of directors for Viatris, the new company that will result from the combination of Mylan and Upjohn, a division of Pfizer, which is expected to occur in mid-2020, subject to receipt of regulatory approvals, Mylan shareholder approval, and the satisfaction of other customary closing conditions. In addition to the previously announced Pfizer-designated appointments of Ian Read and Jim Kilts, Pfizer has appointed current Pfizer board member Don Cornwell, who will resign from the Pfizer board to serve as a director of Viatris upon the close of the transaction. Additionally, Mylan has appointed eight of its own directors to serve on the Viatris board, including JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry Korman, Rajiv Malik, Richard Mark, Mark Parrish and Pauline van der Meer Mohr. As previously announced, the board of Viatris will also include Viatris executive chairman Robert Coury and Viatris CEO Michael Goettler.